Currently, LLY's trailing twelve months (TTM) EPS stands at $28.19, according to the most recent financial reports. In 2025, LLY reported a per-share earnings of $23, which represents an increase compared to the EPS of $11.76 recorded in 2024. LLY recorded an EPS of $8.27 for the quarterly period ending on Mar 31, 2026.
In 2025, ELI LILLY's EPS was $23, an increase of 95.6% from $11.76 in 2024. For the quarter ending Mar 31, 2026, the EPS was $8.27, reflecting a 169.4% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of March 2026 is $28.19. In 2024, the annual EPS was $11.76, showing an increase of 102.1% compared to 2023.
Over the past 12 months, ELI LILLY has recorded an earnings per share growth of 169.4% (YoY, quarterly). Over a three-year span, the company had an average EPS annual growth rate of 49.2% per year. Over the last five years, the company had an average annual EPS growth of 27.5%. When assessed over a ten-year period, LLY's average EPS annual growth was 26.1%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BMY Bristol Myers Squibb Co | 15.48 | 178.7% | 5.3% | N/A |
| PFE Pfizer Inc | 19.79 | -3.5% | -37.4% | -3.7% |
| NVS Novartis AG | 21.49 | 21.8% | 31.2% | 15.2% |
| AMGN Amgen Inc | 23.6 | 88.1% | 5.6% | 2.9% |
| AZN Astrazeneca plc | 26.51 | 45.4% | 46% | 22% |
| JNJ Johnson & Johnson | 26.83 | 90.6% | 17.7% | 14.8% |
| MRK Merck & Co Inc | 32.34 | 8% | 8.4% | 21.2% |
| LLY ELI LILLY & Co | 39.45 | 95.6% | 49.2% | 27.5% |
| ABBV AbbVie Inc | 108.98 | -1.3% | -29.1% | -2.8% |
All data is based on quarterly TTM periods, unless otherwise specified.